Pharma Focus Asia

Astellas to Construct New Pharma Manufacturing Facility in Japan


Astellas Pharma has announced its plans to construct a new pharma manufacturing facility at an investment of around US$91 million.


The third fermentation building is being constructed for the Active Pharmaceutical Ingredient (API) of Prograf (tacrolimus hydrate) at the group's Toyama Technology Center in Japan.

The new facility will have three floors above the ground, with a total floor area of about 7,220m2.

Astellas wants to enhance its production capacity, enabling a stable supply of high-quality products in the future, taking into account the expected steady demand for Prograf.

Prograf has already contributed to medical transplantation globally as a first-line immunosuppressant for organ transplantation.

The drug was previously approved in Japan for rheumatoid arthritis, myasthenia gravis, ulcerative colitis, and lupus nephritis.

The construction of the facility will start in April 2020 and is anticipated to complete in August 2021.


NameAstellas Pharma
BudgetUS$91 million
Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?